A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Ilixadencel (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Immunicum
- 26 Sep 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 09 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.